AGENDIA Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board.
Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics, laboratory medicine and therapeutic development. Currently, he is the Chief Executive Officer and President of BioTrove, a privately held company using innovative platform technologies to dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development. Dr. Luderer is also the Director of Light Micronics, Inc. and a Scientific Advisory Board member at Washington University's Department of Biomedical Engineering, St. Louis, MO.
“We are very pleased to welcome Al to our Supervisory Board," commented Bernhard Sixt, Ph.D., President and Chief Executive Officer of Agendia. “As we continue to expand our U.S. activities, Al’s extensive experience and track record of success in the diagnostics industry will prove extremely valuable to Agendia’s growth."
Previously, Dr. Luderer served as Director, President and Chief Executive Officer of Light Sciences Corporation where he spearheaded the company's combined business, technical and commercial activities. Prior to joining Light Sciences Corporation, Dr. Luderer was President and Chief Operating Officer at bioMerieux, Inc., a world leader in in vitro diagnostics. From 1987 - 1993, Dr. Luderer was at Boehringer Mannheim Corporation (now Roche) where he was named Vice President of Technology Development and Support. He started his work in the sector at Corning Inc. as a key figure negotiating the joint venture diagnostic company Ciba Corning (now Siemens Healthcare Diagnostics).
Dr. Luderer holds a Bachelor of Arts from Drew University and an M.S. and Ph.D. from Rutgers University where he was a National Science Foundation pre-doctoral fellow.
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company’s tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.